Peroxisome proliferator-activated receptors and their ligands in cancer drug-resistance: opportunity or challenge

Anti-Cancer Agents in Medicinal Chemistry

Volumn 16, Issue 12, 2016, Pages 1541-1548

  Yousefi, Bahman ^a   Zarghamia, Nosratollah ^a,b   Samadia, Nasser ^a,b   Majidinia, Maryam ^a,b,c  

^a TABRIZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b TABRIZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c URMIA UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Cancer; Chemotherapy; Drug resistance; P glycoprotein; PPARs; Thiazolidinedione

Indexed keywords

BEZAFIBRATE; CARBACYCLIN; CLOFIBRATE; DRUG METABOLIZING ENZYME; FENOFIBRATE; GEMFIBROZIL; ICOSAPENTAENOIC ACID; LIGAND; LINOLEIC ACID; NAFENOPIN; OLEIC ACID; PALMITIC ACID; PALMITOLEIC ACID; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR DELTA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; STEARIC ACID; ANTINEOPLASTIC AGENT;

CANCER CHEMOTHERAPY; DNA REPAIR; DRUG EFFICACY; HUMAN; MEMBRANE TRANSPORT; NEOPLASM; NONHUMAN; REVIEW; TARGET CELL; ANIMAL; ANTAGONISTS AND INHIBITORS; CHEMICAL STRUCTURE; CHEMISTRY; DRUG EFFECTS; DRUG RESISTANCE; METABOLISM; NEOPLASMS; PATHOLOGY;

ANIMALS; ANTINEOPLASTIC AGENTS; DRUG RESISTANCE, NEOPLASM; HUMANS; LIGANDS; MOLECULAR STRUCTURE; NEOPLASMS; PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS;

EID: 84995932441     PISSN: 18715206     EISSN: 18755992     Source Type: Journal    
DOI: 10.2174/1871520616666160204112941     Document Type: Review

References (102)

1. Holohan, C.; Van Schaeybroeck, S.; Longley, D.B.; Johnston, P. G. Cancer drug resistance: An evolving paradigm. Nat. Rev. Cancer, 2013, 13(10), 714-726.
2. Garraway, L.A.; Janne, P.A. Circumventing cancer drug resistance in the era of personalized medicine. Cancer Discov., 2012, 2(3), 214-226.
3. Szakacs, G.; Annereau, J.P.; Lababidi, S.; Shankavaram, U.; Arciello, A.; Bussey, K.J.; Reinhold, W.; Guo, Y.; Kruh, G.D.; Reimers, M. Predicting drug sensitivity and resistance: Profiling ABC transporter genes in cancer cells. Cancer Cell, 2004, 6(2), 129-137.
4. Szakacs, G.; Paterson, J.K.; Ludwig, J.A.; Booth-Genthe, C.; Gottesman, M.M. Targeting multidrug resistance in cancer. Nat. Rev. Drug Discov., 2006, 5(3), 219-234.
5. Lind, M. Principles of cytotoxic chemotherapy. Medicine, 2004, 32(3), 20-25.
6. Nahta, R.; Yu, D.; Hung, M.C.; Hortobagyi, G.N.; Esteva, F.J. Mechanisms of disease: Understanding resistance to HER2-targeted therapy in human breast cancer. Nat. Clin. Practice Oncol., 2006, 3(5), 269-280.
7. Saraswathy, M.; Gong, S. Different strategies to overcome multidrug resistance in cancer. Biotechnol. Adv., 2013, 31(8), 1397-1407.
8. Longley, D.; Johnston, P. Molecular mechanisms of drug resistance. J. Pathol., 2005, 205(2), 275-292.
9. Fojo, T.; Bates, S. Strategies for reversing drug resistance. Oncogene. 2003, 22(47), 7512-7523.
10. Yousefi, B.; Samadi, N.; Ahmadi, Y. Akt and p53R2, partners that dictate the progression and invasiveness of cancer. DNA Repair, 2014, 22, 24-29.
11. Urquhart, B.L.; Tirona, R.G.; Kim, R.B. Nuclear receptors and the regulation of drug_metabolizing Enzymes and drug transporters: Implications for Interindividual variability in response to drugs. J. Clin. Pharmacol., 2007, 47(5), 566-578.
12. Krishna Vadlapatla, R.; Dutt Vadlapudi, A.; Pal, D.K.; Mitra, A. Mechanisms of drug resistance in cancer chemotherapy: Coordinated role and regulation of efflux transporters and metabolizing enzymes. Curr. Pharmaceut. Desig., 2013, 19(40), 7126-7140.
13. Binkhathlan, Z.; Lavasanifar, A. P-glycoprotein inhibition as a therapeutic approach for overcoming multidrug resistance in cancer: Current status and future perspectives. Curr. Cancer Drug Targ., 2013, 13(3), 326-346.
14. Choi, C.H. ABC transporters as multidrug resistance mechanisms and the development of chemosensitizers for their reversal. Cancer Cell Int., 2005, 5(1), 30.
15. Munoz, M.; Henderson, M.; Haber, M.; Norris, M. Role of the MRP1/ABCC1 multidrug transporter protein in cancer. IUBMB Life, 2007, 59(12), 752.
16. Chen, Z.; Shi, T.; Zhang, L.; Zhu, P.; Deng, M.; Huang, C.; Hu, T.; Jiang, L.; Li, J. Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett., 2016, 370(1), 153-164.
17. Marin, J.G.J.; Briz, O.J.; Monte, M.G.; Blazquez, A.I.R.; Macias, R. Genetic variants in genes involved in mechanisms of chemoresistance to anticancer drugs. Curr. Cancer Drug Targ., 2012, 12(4), 402-438.
18. Koo, S.H.; Lo, Y.L.; Yee, J.Y.; Lee, E.J.D. Genetic and/or nongenetic causes for inter-individual and inter-cellular variability in transporter protein expression: implications for understanding drug efficacy and toxicity. Exp. Opin. Drug Metabol. Toxicol., 2015, 1-17.
19. Liu, L.; Collier, A.C.; Link, J.M.; Domino, K.B.; Mankoff, D.A.; Eary, J.F.; Spiekerman, C.F.; Hsiao, P.; Deo, A.K.; Unadkat, J.D. Modulation of P-glycoprotein at the human blood-brain barrier by quinidine or rifampin treatment: A positron emission tomography imaging study. Drug Metab. Dispos., 2015, 43(11), 1795-1804.
20. Kizek, R.; Adam, V.; Hrabeta, J.; Eckschlager, T.; Smutny, S.; Burda, J.V.; Frei, E.; Stiborova, M. Anthracyclines and ellipticines as DNA-damaging anticancer drugs: Recent advances. Pharmacol. Therapeut., 2012, 133(1), 26-39.
21. Yousefi, B.; Rahmati, M.; Ahmadi, Y. The roles of p53R2 in cancer progression based on the new function of mutant p53 and cytoplasmic p21. Life Sci., 2014, 99(1), 14-17.
22. D'Antonio, C.; Milano, A.; Righini, R.; Onesti, C.E.; Bassanelli, M.; Falcone, R.; Paris, I.; Lauro, S.; Marchetti, P. Pharmacogenomics in lung cancer chemotherapy: A review of what the oncologist should know. Anticancer Res., 2014, 34(10), 5241-5250.
23. Lord, C.J.; Ashworth, A. The DNA damage response and cancer therapy. Nature, 2012, 481(7381), 287-294.
24. Li, G.; Zhang, J.; Jin, K.; He, K.; Zheng, Y.; Xu, X.; Wang, H.; Li, Z.; Yu, X. Estrogen receptor-α36 is involved in development of acquired tamoxifen resistance via regulating the growth status switch in breast cancer cells. Molecular Oncol., 2013, 7(3), 611-624.
25. Hart, C.D.; Migliaccio, I.; Malorni, L.; Guarducci, C.; Biganzoli, L.; Di Leo, A. Challenges in the management of advanced, ERpositive, HER2-negative breast cancer. Nat. Rev. Clin. Oncol., 2015
26. Dekker, T.; Smit, V.; Hooijer, G.; Van de Vijver, M.; Mesker, W.; Tollenaar, R.; Nortier, J.; Kroep, J. Reliability of core needle biopsy for determining ER and HER2 status in breast cancer. Annals Oncol., 2012, mds599.
27. Jakobsen, J.N.; Sorensen J.B. Intratumor heterogeneity and chemotherapy-induced changes in EGFR status in non-small cell lung cancer. Cancer Chemo. Pharmacol., 2012, 69(2), 289-299.
28. Desvergne, B.; Wahli, W. Peroxisome proliferator-activated receptors: Nuclear control of metabolism 1. Endocrine Rev., 1999, 20(5), 649-688.
29. Peters, J.M.; Shah, Y.M.; Gonzalez, F.J. The role of peroxisome proliferator-activated receptors in carcinogenesis and chemoprevention. Nat. Rev. Cancer, 2012, 12(3), 181-195.
30. Ferre, P. The biology of peroxisome proliferator-activated receptors relationship with lipid metabolism and insulin sensitivity. Diabetes, 2004, 53(suppl 1), S43-S50.
31. Pirat, C.l.; Farce, A.; Lebegue, N.; Renault, N.; Furman, C.; Millet, R.G.; Yous, S.D.; Speca, S.; Berthelot, P.; Desreumaux, P. Targeting peroxisome proliferator-activated receptors (PPARs): development of modulators. J. Med. Chem., 2012, 55(9), 4027-4061.
32. Neels, J.G.; Grimaldi, P.A. Physiological functions of peroxisome proliferator-activated receptor β. Physiol. Rev., 2014, 94(3), 795-858.
33. Feige, J.N.; Gelman, L.; Michalik, L.; Desvergne, B.; Wahli, W. From molecular action to physiological outputs: Peroxisome proliferator-activated receptors are nuclear receptors at the crossroads of key cellular functions. Prog. lipid Res., 2006, 45(2), 120-159.
34. Saliani, N.; Darabi, M.; Yousefi, B.; Baradaran, B.; Khaniani, M. S.; Darabi, M.; Shaaker, M.; Mehdizadeh, A.; Naji, T.; Hashemi, M. PPARγ agonist-induced alterations in Δ6-desaturase and stearoyl-CoA desaturase 1: Role of MEK/ERK1/2 pathway. World J. Hepatol., 2013, 5(4), 220.
35. Grygiel-Górniak, B. Peroxisome proliferator-activated receptors and their ligands: Nutritional and clinical implications–a review. Nutr. J., 2014, 13(1), 1-17.
36. Michalik, L.; Wahli, W. PPARs mediate lipid signaling in inflammation and cancer. PPAR Res., 2008, 2008.
37. Fruchart, J.C. Peroxisome proliferator-activated receptor-alpha (PPARα): At the crossroads of obesity, diabetes and cardiovascular disease. Atherosclerosis, 2009, 205(1), 1-8.
38. Neschen, S.; Morino, K.; Dong, J.; Wang-Fischer, Y.; Cline, G. W.; Romanelli, A.J.; Rossbacher, J.C.; Moore, I.K.; Regittnig, W.; Munoz, D.S. n-3 Fatty acids preserve insulin sensitivity in vivo in a peroxisome proliferator–activated receptor-α-dependent manner. Diabetes, 2007, 56(4), 1034-1041.
39. Reddy, J.K.; Rao, M.S. Lipid metabolism and liver inflammation. II. Fatty liver disease and fatty acid oxidation. Am. J. Physiol. Gastrointestinal a Liver Physiol., 2006, 290(5), G852-G858.
40. Poirier, Y.; Antonenkov, V.D.; Glumoff, T.; Hiltunen J.K. Peroxisomal β-oxidation-a metabolic pathway with multiple functions. BBA. Mol. Cell Res., 2006, 1763(12), 1413-1426.
41. Wang, Y.X.; Lee, C.H.; Tiep, S.; Ruth, T.Y.; Ham, J.; Kang, H.; Evans, R.M. Peroxisome-proliferator-activated receptor δ activates fat metabolism to prevent obesity. Cell, 2003, 113(2), 159-170.
42. Huang, W.; Metlakunta, A.; Dedousis, N.; Zhang, P.; Sipula, I.; Dube, J.J.; Scott, D.K.; O'Doherty, R.M. Depletion of liver Kupffer cells prevents the development of diet-induced hepatic steatosis and insulin resistance. Diabetes, 2010, 59(2), 347-357.
43. Bojic, L.A.; Burke, A.C.; Chhoker, S.S.; Telford, D.E.; Sutherland, B.G.; Edwards, J.Y.; Sawyez, C.G.; Tirona, R.G.; Yin, H.; Pickering, J.G. Peroxisome proliferator–Activated receptor δ agonist GW1516 attenuates diet-induced aortic inflammation, insulin resistance, and atherosclerosis in low-density lipoprotein receptor knockout mice. Arteriosclerosis, Thrombosis, and Vascular Biol., 2014, 34(1), 52-60.
44. Bojic, L.A.; Telford, D.E.; Fullerton, M.D.; Ford, R.J.; Sutherland B.G.; Edwards, J.Y.; Sawyez, C.G.; Gros, R.; Kemp, B.E.; Steinberg, G.R. PPAR δ activation attenuates hepatic steatosis in Ldlr−/− mice by enhanced fat oxidation, reduced lipogenesis, and improved insulin sensitivity. J. Lipid Res., 2014, 55(7), 1254-1266.
45. Ngala, R.; Stocker, C.; Roy, A.; Hislop, D.; Wargent, E.; Bell, R.; Hassall, D.; Harling, J.; Billin, A.; Willson, T. A new, highly selective murine peroxisome proliferator_activated receptor δ agonist increases responsiveness to thermogenic stimuli and glucose uptake in skeletal muscle in obese mice. Diabetes Obes. Metab., 2011, 13(5), 455-464.
46. Burkart, E.M.; Sambandam, N.; Han, X.; Gross, R.W.; Courtois, M.; Gierasch, C.M.; Shoghi, K.; Welch, M.J.; Kelly, D.P. Nuclear receptors PPAR β/δ and PPAR α direct distinct metabolic regulatory programs in the mouse heart. J. Clin. Investig., 2007, 117(12), 3930.
47. Yu, B.C.; Chang, C.K.; Ou, H.Y.; Cheng, K.C.; Cheng, J.T. Decrease of peroxisome proliferator-activated receptor delta expression in cardiomyopathy of streptozotocin-induced diabetic rats. Cardiovascular Res., 2008
48. Yang, L.; Zhou, J.; Ma, Q.; Wang, C.; Chen, K.; Meng, W.; Yu, Y.; Zhou, Z.; Sun, X. Knockdown of PPAR δ gene promotes the growth of colon cancer and reduces the sensitivity to bevacizumab in nude mice model. PloSone, 2013, 8, e60715.
49. El Akoum, S. PPAR gamma at the crossroads of health and disease: A masterchef in metabolic homeostasis. Endocrinol. Metab. Synd., 2014, 3(126), 2161-1017.1000126.
50. Kintscher, U.; Law, R.E. PPAR 2 γ -mediated insulin sensitization: the importance of fat versus muscle. Am. J. Physiol. Endocrinol. Metab., 2005, 288(2), E287-E291.
51. Berger, J.; Moller, D.E. The mechanisms of action of PPARs. Annu. Rev. Med., 2002, 53(1), 409-435.
52. Margeli, A.; Kouraklis, G.; Theocharis, S. Peroxisome proliferator activated receptor-γ (PPAR-γ) ligands and angiogenesis. Angiogenesis, 2003, 6(3), 165-169.
53. Panigraphy, D.; Huang, S.; Kieran, M.W.; Kaipainen, A. PPARγ as a therapeutic target for tumor angiogenesis and metastasis. Cancer Biol. Ther., 2005, 4(7), 687-693.
54. Chandrav, H. Structure of the intact PPARγ-RXRα nuclear receptor complex on DNA (J). Nature, 2008, 456(7220), 350.
55. Karagianni, P.; Wong, J. HDAC3: Taking the SMRT-N-CoRrect road to repression. Oncogene, 2007, 26(37), 5439-5449.
56. Nagy, L.; Kao, H.Y.; Chakravarti, D.; Lin, R.J.; Hassig, C.A.; Ayer, D.E.; Schreiber, S.L.; Evans, R.M. Nuclear receptor repression mediated by a complex containing SMRT, mSin3A, and histone deacetylase. Cell, 1997, 89(3), 373-380.
57. Miyata, K.S.; McCaw, S.E.; Meertens, L.M.; Patel, H.V.; Rachubinski, R.A.; Capone, J.P. Receptor-interacting protein 140 interacts with and inhibits transactivation by, peroxisome proliferator-activated receptor α and liver-X-receptor α. Mol. Cell Endocrinol., 1998, 146(1), 69-76.
58. Debevec, D.; Christian, M.; Morganstein, D.; Seth, A.; Herzog, B.; Parker, M.; White, R. Receptor interacting protein 140 regulates expression of uncoupling protein 1 in adipocytes through specific peroxisome proliferator activated receptor isoforms and estrogenrelated receptor α. Mol. Endocrinol., 2007, 21(7), 1581-1592.
59. Wallace, B.D.; Betts, L.; Talmage, G.; Pollet, R.M.; Holman, N.S.; Redinbo, M.R. Structural and functional analysis of the human nuclear xenobiotic receptor pxr in complex with RXRα. J. Mol. Biol., 2013, 425(14), 2561-2577.
60. Roeder, R.G. Transcriptional regulation and the role of diverse coactivators in animal cells. FEBS Lett., 2005, 579(4), 909-915.
61. Reddy, J. K.; Guo D.; Jia Y.; Yu S.; Rao M. S., Nuclear receptor transcriptional coactivators in development and metabolism. Adv. Develop. Biol., 2006, 16, 389-420.
62. Ghosh, A.; Corbett, G.T.; Gonzalez, F.J.; Pahan, K. Gemfibrozil and fenofibrate, Food and drug administration-approved lipidlowering drugs, up-regulate tripeptidyl-peptidase 1 in brain cells via peroxisome proliferator-activated receptor α implications for late infantile batten disease therapy. J. Biol. Chem., 2012, 287(46), 38922-38935.
63. Nseir, W.; Mograbi, J.; Ghali, M. Lipid-lowering agents in nonalcoholic fatty liver disease and steatohepatitis: Human studies. Dig. Dis. Sci., 2012, 57(7), 1773-1781.
64. Rubenstrunk, A.; Hanf, R.; Hum, D.W.; Fruchart, J.C.; Staels, B. Safety issues and prospects for future generations of PPAR modulators. Biochim. et Biophys. Acta Mol. Cell Biol. Lipid., 2007, 1771(8), 1065-1081.
65. Isa, S. The impact of natural and synthetic PPARγ ligands on endoplasmic reticulum stress and the unfolded protein response. 2012, University of Wales.
66. Turner, N.C.; Reis-Filho, J.S. Genetic heterogeneity and cancer drug resistance. Lancet Oncol., 2012, 13(4), e178-e185.
67. Rebucci, M.; Michiels, C. Molecular aspects of cancer cell resistance to chemotherapy. Biochem. Pharmacol., 2013, 85(9), 1219-1226.
68. Johnson, E.F.; Hsu, M.H.; Savas, U.; Griffin, K.J. Regulation of P450 4A expression by peroxisome proliferator activated receptors. Toxicology, 2002, 181, 203-206.
69. Richert, L.; Lamboley, C.; Viollon-Abadie, C.; Grass, P.; Hartmann, N.; Laurent, S.; Heyd, B.; Mantion, G.; Chibout, S.D.; Staedtler, F. Effects of clofibric acid on mRNA expression profiles in primary cultures of rat, mouse and human hepatocytes. Toxicol. Appl. Pharmacol., 2003, 191(2), 130-146.
70. Jennings, P.; Limonciel, A.; Felice, L.; Leonard, M.O. An overview of transcriptional regulation in response to toxicological insult. Arch. Toxicol., 2013, 87(1), 49-72.
71. Buckley, D.B.; Klaassen, C.D. Induction of mouse UDPglucuronosyltransferase mRNA expression in liver and intestine by activators of aryl-hydrocarbon receptor, constitutive androstane receptor, pregnane X receptor, peroxisome proliferator-activated receptor α, and nuclear factor erythroid 2-related factor 2. Drug Metab. Dispos., 2009, 37(4), 847-856.
72. Barbier, O.; Villeneuve, L.; Bocher, V.; Fontaine, C.; Torra, I.P.; Duhem, C.; Kosykh, V.; Fruchart, J.C.; Guillemette, C.; Staels, B. The UDP-glucuronosyltransferase 1A9 enzyme is a peroxisome proliferator-activated receptor α and γ target gene. J. Biol. Chem., 2003, 278(16), 13975-13983.
73. Turgeon, D.; Chouinard, S.; Belanger, P.; Picard, S.; Labbe, J.F.; Borgeat, P.; Belanger, A. Glucuronidation of arachidonic and linoleic acid metabolites by human UDP-glucuronosyltransferases. J. Lipid Res., 2003, 44(6), 1182-1191.
74. Fang, H.L.; Strom, S.C.; Cai, H.; Falany, C.N.; Kocarek, T.A.; Runge-Morris, M. Regulation of human hepatic hydroxysteroid sulfotransferase gene expression by the peroxisome proliferatoractivated receptor α transcription factor. Mol. Pharmacol., 2005, 67(4), 1257-1267.
75. Ou, Z.; Huang, M.; Zhao, L.; Xie, W. Use of transgenic mice in UDP-glucuronosyltransferase (UGT) studies. Drug Metab. Rev., 2010, 42(1), 123-131.
76. Barbier, O.; Duran-Sandoval, D.; Pineda-Torra, I.; Kosykh, V.; Fruchart, J.C.; Staels, B. Peroxisome proliferator-activated receptor α induces hepatic expression of the human bile acid glucuronidating UDP-glucuronosyltransferase 2B4 enzyme. J. Biol. Chem., 2003, 278(35), 32852-32860.
77. Chen, Y.; Tang, Y.; Guo, C.; Wang, J.; Boral, D.; Nie, D. Nuclear receptors in the multidrug resistance through the regulation of drug-metabolizing enzymes and drug transporters. Biochem. Pharmacol., 2012, 83(8), 1112-1126.
78. Szatmari, I.; Vamosi, G.; Brazda, P.; Balint, B.L.; Benko, S.; Szeles, L.; Jeney, V.; Ozvegy-Laczka, C.; Szanto, A.; Barta, E. Peroxisome proliferator-activated receptor γ-regulated ABCG2 expression confers cytoprotection to human dendritic cells. J. Biol. Chem., 2006, 281(33), 23812-23823.
79. Barbier, O.; Fontaine, C.; Fruchart, J.C.; Staels, B. Genomic and non-genomic interactions of PPARα with xenobiotic-metabolizing enzymes. Trends Endocrinol. Metab., 2004, 15(7), 324-330.
80. She, Q.B.; Solit, D.; Basso, A.; Moasser, M.M. Resistance to gefitinib in PTEN-null HER-overexpressing tumor cells can be overcome through restoration of PTEN function or pharmacologic modulation of constitutive phosphatidylinositol 3′-kinase/Akt pathway signaling. Clin. Cancer Res., 2003, 9(12), 4340-4346.
81. Song, M.S.; Salmena, L.; Pandolfi, P.P. The functions and regulation of the PTEN tumour suppressor. Nat. Rev. Mol. Cell Biol., 2012, 13(5), 283-296.
82. Wu, H.; Wang, K.; Liu, W.; Hao, Q. PTEN overexpression improves cisplatin-resistance of human ovarian cancer cells through upregulating KRT10 expression. Biochem. Biophys. Res. Commun., 2014, 444(2), 141-146.
83. Li, Y.; Zhang, D.W.; Lin, D.Q.; Cao, L.Q. Peroxisome proliferator-activated receptor-γ inhibits pancreatic cancer cell invasion and metastasis via regulating MMP-2 expression through PTEN. Mol. Med. Rep., 2015, 12(4), 6255-6260.
84. Pi, W.F.; Guo, X.J.; Su, L.P.; Xu, W.G. Troglitazone upregulates PTEN expression and induces the apoptosis of pulmonary artery smooth muscle cells under hypoxic conditions. Int. J. Mol. Med., 2013, 32(5), 1101-1109.
85. Lin, C.F.; Young, K.C.; Bai, C.H.; Yu, B.C.; Ma, C.T.; Chien, Y.C.; Chiang, C.-L.; Liao, C.S.; Lai, H.W.; Tsao, C.W. Rosiglitazone regulates anti-inflammation and growth inhibition via PTEN. Bio. Med. Res. Int., 2014, 2014.
86. Lee, S.Y.; Hur, G.Y.; Jung, K.H.; Jung, H.C.; Lee, S.Y.; Kim, J. H.; Shin, C.; Shim, J.J.; In, K.H.; Kang, K.H. PPAR-γ agonist increase gefitinib's antitumor activity through PTEN expression. Lung Cancer, 2006, 51(3), 297-301.
87. Tan, Y.; Qin, S.; Hou, X.; Qian, X.; Xia, J.; Li, Y.; Wang, R.; Chen, C.; Yang, Q.; Miele, L. Proteomic-based analysis for identification of proteins involved in 5-fluorouracil resistance in hepatocellular carcinoma. Curr. Pharmaceut. Desig., 2014, 20(1), 81-87.
88. Cao, L.Q.; Wang, X.l.; Wang, Q.; Xue, P.; Jiao, X.Y.; Peng, H.P.; Lu, H.W.; Zheng, Q.; Chen, X.l.; Huang, X.H. Rosiglitazone sensitizes hepatocellular carcinoma cell lines to 5-fluorouracil antitumor activity through activation of the PPARγ signaling pathway. Acta Pharmacol. Sinica, 2009, 30(9), 1316-1322.
89. Mansure, J.J.; Nassim, R.; Chevalier, S.; Szymanski, K.; Rocha, J.; Aldousari, S.; Kassouf, W. A novel mechanism of PPAR gamma induction via EGFR signalling constitutes rational for combination therapy in bladder cancer. PloSone 2013, 8(2), e55997.
90. Girnun, G.D.; Chen, L.; Silvaggi, J.; Drapkin, R.; Chirieac, L.R.; Padera, R.F.; Upadhyay, R.; Vafai, S.B.; Weissleder, R.; Mahmood, U. Regression of drug-resistant lung cancer by the combination of rosiglitazone and carboplatin. Clin. Cancer Res., 2008, 14(20), 6478-6486.
91. To, K.K.; Tomlinson, B. Targeting the ABCG2_overexpressing multidrug resistant (MDR) cancer cells by PPARγ agonists. Bri. J. Pharmacol., 2013, 170(5), 1137-1151.
92. Lin, F.; De Gooijer, M.C.; Roig, E.M.; Buil, L.C.; Christner, S.M.; Beumer, J.H.; Wurdinger, T.; Beijnen, J.H.; Van Tellingen, O. ABCB1, ABCG2, and PTEN determine the response of glioblastoma to temozolomide and ABT-888 therapy. Clin. Cancer Res., 2014, 20(10), 2703-2713.
93. Harkness, T.A. Troglitazone overcomes doxorubicin-resistance in resistant K562 leukemia cells. Leukemia Lymphoma, 2005, 46(8), 1199-1206.
94. Davies, G.F.; Juurlink, B.H.; Harkness, T.A. Troglitazone reverses the multiple drug resistance phenotype in cancer cells. Drug Desig. Develop. Ther., 2009, 3, 79.
95. Charkhpour, M.; Ghavimi, H.; Ghanbarzadeh, S.; Yousefi, B.; Khorrami, A.; Mesgari, M.; Hassanzadeh, K. Protective effect of pioglitazone on morphine-induced neuroinflammation in the rat lumbar spinal cord. J. Biomed. Sci., 2015, 22(1), 1-6.
96. Zhang, M.A.; Rego, D.; Moshkova, M.; Kebir, H.; Chruscinski, A.; Nguyen, H.; Akkermann, R.; Stanczyk, F.Z.; Prat A.; Steinman L., Peroxisome proliferator-activated receptor (PPAR) α and-γ regulate IFNγ and IL-17A production by human T cells in a sex-specific way. Proc. Nat. Acad. Sci., 2012, 109(24), 9505-9510.
97. Wang, L.H.; Yang, X.Y.; Zhang, X.; Farrar, W.L. Inhibition of adhesive interaction between multiple myeloma and bone marrow stromal cells by PPARγ cross talk with NF-κB and C/EBPβ. Blood, 2007, 110(13), 4373-4384.
98. Ghanim, H.; Garg, R.; Aljada, A.; Mohanty, P.; Kumbkarni, Y.; Assian, E.; Hamouda, W.; Dandona, P. Suppression of nuclear factor-κB and stimulation of inhibitor κB by troglitazone: Evidence for an anti-inflammatory effect and a potential antiatherosclerotic effect in the obese. J. Clin. Endocrinol. Metab., 2001, 86(3), 1306-1312.
99. Zhan, L.; Zhang, H.; Zhang, Q.; Woods, C.G.; Chen, Y.; Xue, P.; Dong, J.; Tokar, E.J.; Xu, Y.; Hou, Y. Regulatory role of KEAP1 and NRF2 in PPARγ expression and chemoresistance in human non-small-cell lung carcinoma cells. Free Radic. Biol. Med., 2012, 53(4), 758-768.
100. Girnun, G.D.; Naseri, E.; Vafai, S.B.; Qu, L.; Szwaya, J.D.; Bronson, R.; Alberta, J.A.; Spiegelman, B.M. Synergy between PPARγ ligands and platinum-based drugs in cancer. Cancer Cell 2007, 11(5), 395-406.
101. Tencer, L.; Burgermeister, E.; Ebert, M.P.; Liscovitch, M. Rosiglitazone induces caveolin-1 by PPARγ-dependent and PPREindependent mechanisms: the role of EGF receptor signaling and its effect on cancer cell drug resistance. Anticancer Res., 2008, 28(2A), 895-906.
102. Pelicano, H.; Carney, D.; Huang, P. ROS stress in cancer cells and therapeutic implications. Drug Resist. Updates, 2004, 7(2), 97-110.